Test Information

ARUP’s advanced testing and BRCA1 and BRCA2 expertise support patients battling breast cancer and cancer survivors.

The ARUP Clinical Investigations team includes (back row, left to right) Galina Chernova, Kendall Ence, Qian Guo, Stephanie Harrison, and Jacob Brugger; (middle row, left to right) Nicholas Mangome, Chau Trinh, Ani Schjelderup, Carrie Pederson, and Amy Ballard; (front row, left to right) Toni Pollock, Katharina Pennington, Karis Tran, and Rachel Lloyd.

Hepatitis delta virus (HDV), which affects an estimated 48 to 72 million people worldwide, results in the most severe form of viral hepatitis-induced liver disease.

ARUP medical directors will discuss our newly expanded test menu based on the latest research, guidelines, and technology.

ARUP’s validation of a plasma-based immunoassay to detect Alzheimer’s disease pathology was selected as a 2025 Academy Distinguished Abstract. Nicholas Spies, MD, received the 2025 Outstanding Scientific Achievements by a Young Investigator Merit Award.

Sherin Shaaban, MD, PhD, MSci, FACMG, ARUP medical director of Pharmacogenomics and Molecular Genetics, is the expert overseeing two ARUP tests that detect nine well-studied variants of DPYD.